Regeneron Pharmaceuticals Inc

Day range

$801.22 – $819.09

Open

$819.09

Prev close

$819.09

Volume

527.74K

Market cap

$84.33B

Shares out

101.14M

P/E

19.48

P/S

5.43

P/B

2.66

P/FCF

22.43

ROE

13.7%

ROA

10.4%

Debt/Equity

0.09

Div yield

0.45%

As of Oct 22, 2026

• Deal agreementsOct 6, 2026

  The Sixth Amendment... amends the Amended and Restated License and Collaboration Agreement... Pursuant to the Sixth Amendment, Sanofi will make an upfront payment to Regeneron of $1.0 billion. In addition, ... Regeneron will be entitled to receive up to an additional $7.0 billion of payments in the aggregate upon the achievement of certain development, regulatory, and commercial milestones.

• Executive leadershipSep 30, 2026

  Awards are capped at 2,700,000 PSUs (CEO) and 2,900,000 PSUs (CSO), regardless of greater performance. ... Executives must remain continuously employed or otherwise provide service through the applicable earnout measurement dates during the full 10-year performance period ending December 31, 2035 (subject to certain qualifying termination protections).

• Earnings and performanceJul 6, 2026

  Regeneron currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles ('GAAP') and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development ('IPR&D') charge of approximately $127 million on a pre-tax basis. Regeneron's results for the second quarter 2026 have not been finalized and are subject to Regeneron's financial statement closing procedures.

• Shareholder meetingsJun 17, 2026

  At the 2026 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. held on June 12, 2026, Regeneron's shareholders voted on the matters set forth below. The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders based upon the following votes: Joseph L. Goldstein, M.D., Christine A. Poon, David P. Schenkein, M.D., Craig B. Thompson, M.D., and Huda Y. Zoghbi, M.D.

• Earnings and performanceApr 8, 2026

  Regeneron currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles ('GAAP') and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development ('IPR&D') charge of approximately $102 million on a pre-tax basis... Regeneron's results for the first quarter 2026 have not been finalized and are subject to Regeneron's financial statement closing procedures.

• PFEPfizer Inc.-1.28%
• VRTXVertex Pharmaceuticals Inc-2.09%
• LLYEli Lilly & Co.-2.54%
• MRNAModerna, Inc. Common Stock-1.25%
• AMGNAmgen Inc-1.79%
• NTLAIntellia Therapeutics, Inc+0.45%
• GILDGilead Sciences Inc-0.73%
• MRKMerck & Co., Inc.-1.34%

Days to cover

2.5

Short interest

2.15M

Avg volume

863.84K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Facing Investing Fears
  positiveThe Motley Fool· Oct 23, 2026
• Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  neutralZacks Investment Research· Oct 23, 2026
• Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
  positiveThe Motley Fool· Oct 19, 2026
• Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
  positiveThe Motley Fool· Oct 17, 2026
• Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
  positiveGlobeNewswire Inc.· Oct 16, 2026